Thymidine kinase deficient cells with decreased TTP pools are hypersensitive to DNA alkylating agents

被引:9
作者
Wakazono, Y
Kubota, M
Furusho, K
Liu, L
Gerson, SL
机构
[1] KYOTO UNIV,DEPT PEDIAT,SAKYO KU,KYOTO 606,JAPAN
[2] CASE WESTERN RESERVE UNIV,SCH MED,CTR CANC,CLEVELAND,OH 44106
[3] CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106
来源
MUTATION RESEARCH-DNA REPAIR | 1996年 / 362卷 / 01期
关键词
thymidine kinase; alkylating agent; TTP pool; cytotoxicity; mutation frequency;
D O I
10.1016/0921-8777(95)00042-9
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The effect of mutational loss of thymidine kinase (TK) on the sensitivity to alkylating agents was investigated in promyelocytic, HL-60, and T-lymphoblastoid, Molt-3, human leukemia cell lines, Although both cell lines exhibited approx. 1% residual TK activity, only HL-60 TK deficient cells had a decreased intracellular TTP pool, i.e,, 20% of that of the wild-type. When treated with N-methyl-N'-nitronitrosoguanidine or ethyl methanesulfonate, HL-60 TK deficient cells showed significantly increased killing and mutation frequencies at the hypoxanthine-guanine phosphoribosyl transferase (HGPRT) locus relative than did the wild-type. Pretreatment of cells with O-6-benzylguanine, an inhibitor of O-6-alkylguanine-DNA alkyltransferase, partially abolished those differences. Molt-3 wild-type and TK deficient cells had similar cell survivals and HGPRT mutation frequencies following treatment with alkylating agents. These results indicate that TK deficiency, only when a concomitant decrease of TTP pool is detected, plays a pivotal role in the sensitivity to the cytotoxic and mutagenic effects of alkylating agents.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 29 条
[1]  
ALNABULSI I, 1994, CANCER RES, V54, P5614
[2]  
AYUSAWA D, 1983, CANCER RES, V43, P814
[3]  
BRONSTEIN SM, 1992, CANCER RES, V52, P3851
[4]  
CARSON DA, 1980, J IMMUNOL, V124, P8
[5]   DEPLETION OF MAMMALIAN OXYGEN-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY BY OXYGEN-6-BENZYLGUANINE PROVIDES A MEANS TO EVALUATE THE ROLE OF THIS PROTEIN IN PROTECTION AGAINST CARCINOGENIC AND THERAPEUTIC ALKYLATING-AGENTS [J].
DOLAN, ME ;
MOSCHEL, RC ;
PEGG, AE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (14) :5368-5372
[6]   QUANTITATIVE ASSAY FOR MUTATION IN DIPLOID HUMAN-LYMPHOBLASTS USING MICROTITER PLATES [J].
FURTH, EE ;
THILLY, WG ;
PENMAN, BW ;
LIBER, HL ;
RAND, WM .
ANALYTICAL BIOCHEMISTRY, 1981, 110 (01) :1-8
[7]  
GALLAGHER R, 1979, BLOOD, V54, P713
[8]   COMPARISON OF O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY BASED ON CELLULAR DNA CONTENT IN HUMAN, RAT AND MOUSE-TISSUES [J].
GERSON, SL ;
TREY, JE ;
MILLER, K ;
BERGER, NA .
CARCINOGENESIS, 1986, 7 (05) :745-749
[9]  
KARRAN P, 1990, CANCER RES, V50, P1532
[10]   MUTAGENESIS AND DEOXYRIBONUCLEOTIDE POOL IMBALANCE [J].
KUNZ, BA .
MUTATION RESEARCH, 1988, 200 (1-2) :133-147